<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1244</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12574375</PubmedId>
            <Abstract>CD4 T cells are critical for resistance to Mycobacterium tuberculosis infection, but how effective T cell responses are maintained during chronic infection is not well understood. To address this question we examined the CD4 T cell response to a peptide from ESAT-6 during tuberculosis infection in the mouse. The ESAT-6(1-20)/IA(b)-specific CD4 T cell response in the lungs, mediastinal lymph nodes, and spleen reached maxima 3-4 wk postinfection, when the bacteria came under the control of the immune response. Once chronic infection was established, the relative frequencies of Ag-specific CD4 T cells were maintained at nearly constant levels for at least 160 days. ESAT-6(1-20)/IA(b)-specific CD4 T cells that responded in vitro expressed activation markers characteristic of chronically activated effector cells and used a limited Vbeta repertoire that was clonally stable in vivo for at least 12 wk. 5-Bromo-2-deoxyuridine incorporation studies indicated a relatively high rate of cell division among both total CD4 and ESAT-6(1-20)/IA(b)-specific CD4 T cells during acute infection, but the degree of 5-bromo-2-deoxyuridine incorporation by both the CD4 T cells and the Ag-specific cells declined at least 3-fold during chronic infection. The data indicate that the peripheral ESAT-6(1-20)/IA(b)-specific CD4 T cell response to M. tuberculosis is characterized during the acute phase of infection by a period of extensive proliferation, but once bacterial control is achieved, this is followed during chronic infection by an extended containment phase that is associated with a persistent response of activated, yet more slowly proliferating, T cells.</Abstract>
            <ArticleYear>2003</ArticleYear>
            <ArticlePages>2046-52</ArticlePages>
            <ArticleTitle>Persistence and turnover of antigen-specific CD4 T cells during chronic tuberculosis infection in the mouse.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Winslow</LastName>
                    <ForeName>Gary M</ForeName>
                </Author>
                <Author>
                    <LastName>Roberts</LastName>
                    <ForeName>Alan D</ForeName>
                </Author>
                <Author>
                    <LastName>Blackman</LastName>
                    <ForeName>Marcia A</ForeName>
                </Author>
                <Author>
                    <LastName>Woodland</LastName>
                    <ForeName>David L</ForeName>
                </Author>
            </Authors>
            <Affiliations>Wadsworth Center, New York State Department of Health, 120 New Scotland Avenue, Albany, NY 12201, USA. gary.winslow@wadsworth.org.</Affiliations>
            <ArticleChemicalList>Antigens, Bacterial;Bacterial Proteins;Biomarkers;ESAT-6 protein, Mycobacterium tuberculosis;Epitopes, T-Lymphocyte;Peptide Fragments</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigens, Bacterial(analysis; immunology); Bacterial Proteins; Biomarkers(analysis); CD4-Positive T-Lymphocytes(immunology; microbiology; pathology); Cell Division(immunology); Cell Survival(immunology); Chronic Disease; Epitopes, T-Lymphocyte(analysis; immunology); Lung(immunology; microbiology; pathology); Lymphocyte Activation(immunology); Lymphocyte Count; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis(immunology); Peptide Fragments(analysis; immunology); T-Lymphocyte Subsets(immunology; microbiology; pathology); Thymus Gland(immunology; microbiology; pathology); Tuberculosis(immunology; microbiology; pathology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>170</Volume>
                <Issue>4</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>ESAT-6 1-20</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MTEQQWNFAGIEAAASAIQG</LinearSequence>
                        <StartingPosition>1</StartingPosition>
                        <EndingPosition>20</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P0A564.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1773</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Provided by author</LocationOfData>
                <EpitopeId>42797</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>20</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2 and 3</LocationOfData>
                        <TCellId>21011</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:399</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M. tuberculosis</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>181</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>ESAT-6 1-20</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MTEQQWNFAGIEAAASAIQG</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>20</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A564.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific CD4+ INFg-producucing cells were demonstrated in the lung after aerosol infection with M. tuberculosis at day 21 postinfection by flow cytometry. The epitope-sepecific CD4+ cells were shown to have the phenotype of chronically activated cells, being CD44 high, CD62L low, CD69low, CD25 low, CD45RB intermediate and with 60% of the cells CD43+.The response to the epitope was also shown to be oligoclonal through the demonstration of the use of four different Vbeta chains (Vb3, Vb6, Vb8, and Vb14).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 4, 5, and 6</LocationOfData>
                        <TCellId>21012</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:399</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M. tuberculosis</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>181</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>ESAT-6 1-20</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MTEQQWNFAGIEAAASAIQG</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>20</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A564.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>200</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Proliferation of epitope-specific IFNg-producing CD4+ cells was observed with a peak in proliferation occurring around day 28 postinfection followed by a decrease in the proliferation rate. The prolonged epitope-specific response was shown to derive from existing T cells through thymectomized mice having similar numbers of epitope-specific cells with the same or a lower rate of proliferation as non-thymectomized mice.  BrdU was administered to the mice either i.p. on day 21 postinfection or via the drinking water for 7 days starting on day 21 postinfection.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>20952</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:399</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M. tuberculosis</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lung</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>181</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -MHC subset identification</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>ESAT-6 1-20</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MTEQQWNFAGIEAAASAIQG</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>20</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A564.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific CD4+ INFg-producucing cells were demonstrated in the lung after aerosol infection with M. tuberculosis by day 21 postinfection and remained up to 166 days after infection. Similar results were found in cells from mediastinal lymph node (MLN) and spleen although with lower frequencies.  Lymphocytes from infected tissues were cultured with the epitope, irradiated splenocytes, and rIL-2 for 40 hours.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

